Market Cap 8.40B
Revenue (ttm) 1.22B
Net Income (ttm) 73.40M
EPS (ttm) N/A
PE Ratio 31.06
Forward PE 30.49
Profit Margin 6.02%
Debt to Equity Ratio 0.18
Volume 1,305,800
Avg Vol 2,195,890
Day's Range N/A - N/A
Shares Out 156.77M
Stochastic %K 78%
Beta 1.40
Analysts Strong Sell
Price Target $64.57

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors,...

Industry: Biotechnology
Sector: Healthcare
Phone: 612 379 8854
Fax: 612 656 4400
Address:
614 McKinley Place N.E., Minneapolis, United States
JarvisFlow
JarvisFlow Aug. 7 at 2:45 PM
RBC Capital has updated their rating for Bio-Techne ( $TECH ) to Sector Perform with a price target of 61.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 2:26 PM
$TECH beats earnings estimates, but the stock dips — what's going on? 🤔 Adjusted EPS of 53 cents beat the Zacks Consensus Estimate by 6%, with revenue up 3.5% year over year. Yet, shares dropped 1.2% pre-market as gross margins contracted and operating income turned negative. 📉 Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2672794/bio-techne-q4-earnings-beat-estimates-gross-margin-down-stock-falls?cid=sm-stocktwits-2-2672794-body-6294&ADID=SYND_STOCKTWITS_TWEET_2_2672794_BODY_6294
0 · Reply
CrispDry
CrispDry Aug. 6 at 1:43 PM
$TECH complete dogsh*t $PRGO
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 12:07 PM
$TECH beats on Q4 earnings — so why is the stock dropping? The company topped estimates, but gross margin declined and shares sold off on the report. Full breakdown of what moved the stock 👉 https://www.zacks.com/stock/news/2672794/bio-techne-q4-earnings-beat-estimates-gross-margin-down-stock-falls?cid=sm-stocktwits-2-2672794-teaser-6210&ADID=SYND_STOCKTWITS_TWEET_2_2672794_TEASER_6210
0 · Reply
Estimize
Estimize Aug. 6 at 10:00 AM
Wall St is expecting 0.44 EPS for $TECH Q1 [Reporting 11/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co
0 · Reply
OptionRunners
OptionRunners Aug. 5 at 6:44 PM
$TECH Buyer of the August 15th $50 calls (ITM) 400 times for $5.90 ahead of earnings tomorrow morning. Repeat flow
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 2:32 PM
$TECH Q4 earnings: Can Bio-Techne defy the odds? 🤔 🌐 Revenue estimate up 3.7% YoY to $317.4M 🔍 Spatial Biology segment set for modest growth ⚠️ Zacks Rank #4 (Sell) + Earnings ESP of 0.00% = cautious outlook In-depth analysis here 👉 https://www.zacks.com/stock/news/2662135/bio-techne-q4-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2662135-body-5663&ADID=SYND_STOCKTWITS_TWEET_2_2662135_BODY_5663
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 1:27 PM
Q4 setup for $TECH — bullish or bust? Investors are eyeing Bio-Techne’s upcoming Q4 report to gauge revenue trends and margin stability in a tough biotech tape. Full earnings preview here 👉 https://www.zacks.com/stock/news/2662135/bio-techne-q4-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2662135-teaser-5630&ADID=SYND_STOCKTWITS_TWEET_2_2662135_TEASER_5630
0 · Reply
OptionRunners
OptionRunners Jul. 31 at 2:43 PM
$TECH Buyer of the August 15th $55 calls (ITM) 1,000 times for $5.00 ahead of earnings on 8/6
0 · Reply
lanky9622
lanky9622 Jul. 29 at 9:24 PM
$XDC.X Just got the inside scoop on a hot new quantum startup, PsiPi.Ai. They’re bringing novel quantum-field modulation tech that could challenge the dominant players. Keep an eye on this one! 🔥 $IONQ $RGTI $IBM #Quantum #Startups #DeepTech $TECH
1 · Reply
Latest News on TECH
Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript

Aug 6, 2025, 12:52 PM EDT - 11 days ago

Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript


BIO-TECHNE DECLARES DIVIDEND

Aug 6, 2025, 6:30 AM EDT - 11 days ago

BIO-TECHNE DECLARES DIVIDEND


Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

Aug 6, 2025, 6:30 AM EDT - 11 days ago

Bio-Techne Releases Fourth Quarter Fiscal 2025 Results


Bio-Techne Announces Exosome Diagnostics Divestiture

Aug 5, 2025, 4:30 PM EDT - 12 days ago

Bio-Techne Announces Exosome Diagnostics Divestiture


Bio-Techne to Present at Investor Conferences

May 29, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne to Present at Investor Conferences


Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

May 7, 2025, 10:38 AM EDT - 3 months ago

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript


BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

May 7, 2025, 6:30 AM EDT - 3 months ago

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM


BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

May 7, 2025, 6:30 AM EDT - 3 months ago

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS


Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 2:24 PM EST - 6 months ago

Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript


Bio-Techne Declares Dividend

Feb 5, 2025, 6:30 AM EST - 6 months ago

Bio-Techne Declares Dividend


Bio-Techne Releases Second Quarter Fiscal 2025 Results

Feb 5, 2025, 6:30 AM EST - 6 months ago

Bio-Techne Releases Second Quarter Fiscal 2025 Results


Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

Feb 4, 2025, 7:00 AM EST - 6 months ago

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors


ScaleReady awards a G-Rex® Grant to Moonlight Bio

Dec 18, 2024, 7:00 AM EST - 8 months ago

ScaleReady awards a G-Rex® Grant to Moonlight Bio


JarvisFlow
JarvisFlow Aug. 7 at 2:45 PM
RBC Capital has updated their rating for Bio-Techne ( $TECH ) to Sector Perform with a price target of 61.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 2:26 PM
$TECH beats earnings estimates, but the stock dips — what's going on? 🤔 Adjusted EPS of 53 cents beat the Zacks Consensus Estimate by 6%, with revenue up 3.5% year over year. Yet, shares dropped 1.2% pre-market as gross margins contracted and operating income turned negative. 📉 Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2672794/bio-techne-q4-earnings-beat-estimates-gross-margin-down-stock-falls?cid=sm-stocktwits-2-2672794-body-6294&ADID=SYND_STOCKTWITS_TWEET_2_2672794_BODY_6294
0 · Reply
CrispDry
CrispDry Aug. 6 at 1:43 PM
$TECH complete dogsh*t $PRGO
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 12:07 PM
$TECH beats on Q4 earnings — so why is the stock dropping? The company topped estimates, but gross margin declined and shares sold off on the report. Full breakdown of what moved the stock 👉 https://www.zacks.com/stock/news/2672794/bio-techne-q4-earnings-beat-estimates-gross-margin-down-stock-falls?cid=sm-stocktwits-2-2672794-teaser-6210&ADID=SYND_STOCKTWITS_TWEET_2_2672794_TEASER_6210
0 · Reply
Estimize
Estimize Aug. 6 at 10:00 AM
Wall St is expecting 0.44 EPS for $TECH Q1 [Reporting 11/04 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co
0 · Reply
OptionRunners
OptionRunners Aug. 5 at 6:44 PM
$TECH Buyer of the August 15th $50 calls (ITM) 400 times for $5.90 ahead of earnings tomorrow morning. Repeat flow
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 2:32 PM
$TECH Q4 earnings: Can Bio-Techne defy the odds? 🤔 🌐 Revenue estimate up 3.7% YoY to $317.4M 🔍 Spatial Biology segment set for modest growth ⚠️ Zacks Rank #4 (Sell) + Earnings ESP of 0.00% = cautious outlook In-depth analysis here 👉 https://www.zacks.com/stock/news/2662135/bio-techne-q4-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2662135-body-5663&ADID=SYND_STOCKTWITS_TWEET_2_2662135_BODY_5663
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 1:27 PM
Q4 setup for $TECH — bullish or bust? Investors are eyeing Bio-Techne’s upcoming Q4 report to gauge revenue trends and margin stability in a tough biotech tape. Full earnings preview here 👉 https://www.zacks.com/stock/news/2662135/bio-techne-q4-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2662135-teaser-5630&ADID=SYND_STOCKTWITS_TWEET_2_2662135_TEASER_5630
0 · Reply
OptionRunners
OptionRunners Jul. 31 at 2:43 PM
$TECH Buyer of the August 15th $55 calls (ITM) 1,000 times for $5.00 ahead of earnings on 8/6
0 · Reply
lanky9622
lanky9622 Jul. 29 at 9:24 PM
$XDC.X Just got the inside scoop on a hot new quantum startup, PsiPi.Ai. They’re bringing novel quantum-field modulation tech that could challenge the dominant players. Keep an eye on this one! 🔥 $IONQ $RGTI $IBM #Quantum #Startups #DeepTech $TECH
1 · Reply
shitzushimazu
shitzushimazu Jul. 28 at 2:20 AM
$TECH turn up time?
0 · Reply
jtrader8000
jtrader8000 Jul. 25 at 5:46 AM
$TECH TECH - great ticker, good bounce off lows which isnt far away so very easy to manage downside from here, has been on big runs before 2022 highs, so hopefully this is the start of another run
0 · Reply
Fizz26
Fizz26 Jul. 24 at 11:16 PM
$DJIA $TECH great balance sheet and undervalued
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 3:15 PM
Scotiabank updates rating for Bio-Techne ( $TECH ) to Sector Outperform, target set at 90 → 75.
0 · Reply
Investogainerresearch
Investogainerresearch Jul. 10 at 6:29 PM
$TECHM.NSE Fundamental View- $TECH Mahindra Ltd. (TECHM) – Fundamental Summary (As of July 2025): Tech Mahindra is a leading Indian IT services and consulting company under the Mahindra Group, specializing in digital transformation, telecom solutions, and enterprise technology services. The $COMPANY has a strong client base across telecom, BFSI, healthcare, and manufacturing sectors globally. In FY24–25, $TECHM witnessed muted revenue growth due to challenges in the telecom vertical and a delay in discretionary IT spending from clients. However, the company is focusing on margin improvement through operational efficiency and cost optimization. Its return ratios—ROE and ROCE—have come under slight pressure but remain stable at around 14–16%. $TECHM maintains a debt-free balance sheet with strong cash reserves, and regularly rewards shareholders via dividends and buybacks. With new leadership and a renewed focus on next-gen tech areas like AI, 5G, and cloud services, the $COMPANY is positioning itself for a turnaround. $TECHM offers long-term potential, though near-term performance may remain range-bound due to sectoral headwinds. Technical View- As seen on the daily chart, $TECH Mahindra has witnessed a decline for the past two sessions and is currently trading within the range of its 14-day and 55-day EMAs. Today, the $STOCK opened at ₹1617.30, made an intraday high of ₹1617.30, a low of ₹1590.10, and closed at ₹1600.10. The Parabolic SAR has shifted above the price candles, indicating short-term bearishness. MACD is also showing a weakening trend, and RSI stands around 40.91, reflecting fading momentum. The price is now testing the 100-day EMA zone as a support level. With Q1 results scheduled on 16th July, the $STOCK is seen sustaining near a strong support zone. Any dip around ₹1560—which also aligns with its 200-day EMA—could be a good buying opportunity. With a stoploss of ₹1550, the $STOCK may potentially retest its 14-day EMA and move toward ₹1690–1700 levels in the short term. Warning- https://investogainerresearch.com/disclaimer https://investogainerresearch.com/standarddisclouser https://investogainerresearch.com/investorcharter
0 · Reply
Fizz26
Fizz26 Jul. 10 at 3:12 PM
$DJIA $TECH let’s goooo
0 · Reply
JarvisFlow
JarvisFlow Jul. 9 at 12:00 PM
TD Cowen has updated their rating for Bio-Techne ( $TECH ) to Buy with a price target of 65.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 8 at 2:35 PM
Bio-Techne ($TECH) cements its leadership in the booming $2.35B in situ hybridization market with 70,000+ RNAscope probes. While margins face pressure, their spatial biology edge and Leica partnership could be the catalyst needed to justify that premium valuation. When your tech becomes the gold standard, pricing power follows. https://www.prnewswire.com/news-releases/2-35-billion-by-2030-why-in-situ-hybridization-is-revolutionizing-molecular-diagnostics--marketsandmarkets-302499850.html
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 1:17 PM
$TECH's new partnership with USP — a significant milestone for gene therapy development? 🤔 Bio-Techne's deal to distribute USP's mAb and AAV standards could enhance quality and compliance in biotherapeutic development. With a favorable earnings yield and a history of surprises, TECH aims to support advancements despite recent declines. Discover the full impact on TECH's prospects 👉 https://www.zacks.com/commentary/2557506/bio-technes-new-usp-deal-on-mab-and-gene-therapy-may-boost-its-stock?cid=sm-stocktwits-2-2557506-body-405&ADID=SYND_STOCKTWITS_TWEET_2_2557506_BODY_405
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 11:50 AM
New partnership could be a game-changer for $TECH 🧬📈 TECH is teaming up with USP to advance mAb and gene therapy testing — aiming to streamline analytics and improve product quality. Find out what this means for the stock’s upside 👉 https://www.zacks.com/stock/news/2557506/bio-technes-new-usp-deal-on-mab-and-gene-therapy-may-boost-its-stock?cid=sm-stocktwits-2-2557506-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2557506_TEASER
0 · Reply
Fizz26
Fizz26 Jun. 26 at 5:47 PM
$DJIA $TECH ! Go long
0 · Reply
shitzushimazu
shitzushimazu Jun. 25 at 11:34 PM
$TECH really disappointed techne
0 · Reply